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The development of pharmaceutical HIV prevention technologies (PPTs) over the last five years has generated intense
interest from a range of stakeholders. There are concerns that these clinical and pharmaceutical interventions are
proceeding with insufficient input of the social sciences. Hence key questions around implementation and evaluation
remain unexplored whilst biomedical HIV prevention remains insufficiently critiqued or theorised from sociological as
well as other social science perspectives. This paper presents the results of an expert symposium held in the UK to
explore and build consensus on the role of the social sciences in researching and evaluating PPTs in this context. The
symposium brought together UK social scientists from a variety of backgrounds. A position paper was produced and
distributed in advance of the symposium and revised in the light this consultation phase. These exchanges and the
emerging structure of this paper formed the basis for symposium panel presentations and break-out sessions. Recordings
of all sessions were used to further refine the document which was also redrafted in light of ongoing comments from
symposium participants. Six domains of enquiry for the social sciences were identified and discussed: self, identity and
personal narrative; intimacy, risk and sex; communities, resistance and activism; systems, structures and institutions;
economic considerations and analyses; and evaluation and outcomes. These are discussed in depth alongside
overarching consensus points for social science research in this area as it moves forward.
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Background
Pharmaceutical HIV prevention involves the use of
antiretroviral (ARV) drugs by HIV-negative and HIV-
positive individuals to reduce HIV acquisition and
transmission, respectively. Current pharmaceutical HIV
prevention technologies (PPTs) include pre-exposure
prophylaxes (PrEP) – administered either orally or
topically, post-exposure prophylaxes (PEP) and treat-
ment as prevention (TasP). Clinical science has delivered
a consistently high effect size for TasP and a range from
0% to 73% reduction in incidence across placebo-
controlled PrEP trials (Mayer, 2014; McCormack, Gafos,
Desai, & Cohen, 2014). Although trial evidence for PEP
is less robust, it has been widely used as a PPT for some
time now (McCormack et al., 2014).
Whilst some have hailed PPTs as having the potential
to end the AIDS pandemic (Havlir & Beyrer, 2012),
others are circumspect (Miller, Powers, Smith, & Cohen,
2013; Wilson, 2012). Reservations sometimes focus on
epidemiological factors, with the point being made that
many new instances of exposure and transmission
emanate from those most recently infected who have
not yet had the opportunity to test for HIV (Cohen, Dye,
Fraser, Miller, & Powers, 2012; Delpech, 2012). Others
focus on implementation and acceptability, citing
psychosocial and interpersonal factors mediating indivi-
duals’ interactions with HIV treatments and their capa-
city to use PPTs (Adam, Maticka-Tyndale, & Cohen,
2003; Keogh, 2013; Persson, 2012; Rosengarten, Imrie,
Flowers, Davis, & Hart, 2004). There are concerns that
PPTs are being considered solely as a clinical interven-
tion devoid of social context, where both effectiveness
and the passive compliance of the target population are
assumed (Adam, 2011; Davis & Squire, 2010; Kippax &
Stephenson, 2012; Nguyen, Bajos, Dubois-Arberd,
O’Malleye, & Pirklef, 2011; Seeley et al., 2012; Squire,
2012). With only a few examples of research and com-
mentary on the topic (Bourne, Dodds, Weatherburn, &
Keogh, 2011; Davis & Squire, 2010; Imrie, Elford,
Kippax, & Hart, 2007; Mykhalovskiy & Rosengarten,
2009; Patton, 2011; Rosengarten, 2009), social sciences
in the developed Global North have not kept in step with
clinical and epidemiological developments with key
questions around implementation remaining unexamined
(Kippax & Stephenson, 2012; Young & McDaid, 2014).
These concerns are of relevance in the UK context, a
high-income country with a concentrated HIV epidemic.
An estimated 98,400 people are living with HIV in the
UK (Aghaizu, Brown, Nardone, Gill, & Delpech, 2013).
Men who have sex with men (MSM) and Black African
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men and women are the two groups most affected by
HIV making up approximately 42% and 32% of the
overall UK population of people with HIV (PWHIV),
respectively. Free, accessible HIV treatment and care has
resulted in high treatment coverage in the UK with an
estimate of 85% of the diagnosed population in care.
Approximately 48% of the entire HIV population had an
undetectable viral load in 2011 (Aghaizu et al., 2013).
Clinical guidelines in the UK have been updated to take
account of the efficacy of TasP with the expectation that
all those accessing clinical services are to be fully
informed about the prevention benefits of treatment
(Williams, 2014). Moreover, there is also an imple-
mentation study of PrEP among MSM being undertaken
in the UK by the Medical Research Council (see http://
www.proud.mrc.ac.uk/).
This paper represents the culmination of a process
that focused around an expert symposium of HIV social
scientists held in London in December 2012. It was
motivated by a desire to ensure that HIV prevention in
the UK would not emerge from this “biomedical
moment” with insufficient support critique and theorisa-
tion from the social sciences. The process involved
nearly 40 social scientists specialising in HIV from a
range of backgrounds: cultural sociologists, health ser-
vice researchers, psychologists, economic sociologists,
demographers, mathematical modellers, policy analysts,
social epidemiologists and those with expertise in
complex evaluations. Its purpose was to explore and
build consensus on the role of the social sciences in
researching and evaluating new and emerging HIV
prevention technologies in the UK and to produce a
discussion document to inform future work.
Rather than using established consensus-building
approaches such as Delphi or nominal group techniques
(Van Teijlingen, Pitchforth, Bishop, & Russell, 2006),
the process was less formal, though still systematic.
A draft discussion document was prepared by the authors
in advance of the symposium and distributed to all
participants prior to the symposium and comments
invited. These comments were integrated into a final
pre-symposium draft. The symposium consisted of a
panel of presenters who were invited to give a back-
ground to each thematic area followed by break-out
workshops where subgroups engaged in facilitated dis-
cussion around each theme. These groups then fed back
to the main symposium. The panel presentations and
group feedback were recorded audio-visually and are
available online (see http://vimeo.com/61718033). The
subgroup discussions were audio-recorded. These
recordings were used to amend the discussion document
further with subsequent drafts redistributed to workshop
participants for further comments. Here we present the
final discussion document emerging from this extensive
consultative process. It is important to state the
limitations of this process. Attendees were selected for
their expertise and experience in this area. Although
the conclusions and consensus points presented in this
paper are those of an expert group and are evidence-
based, they are also still opinion and as such, are open to
challenge.
Domain 1: self, identity and personal narrative
Sociologists have worked to describe the ways in which
individuals engage in “identity work” to forge identities
and responses to the epidemic which reinforce or under-
mine overarching social and cultural norms (Baumgartner,
2007; Flowers et al., 2006; Green & Sobo, 2000; Halkitis
et al., 2005). Thus, we articulate the lived experience of
‘being’ HIV-positive or HIV-negative and describe selves
who are sick/healthy, responsible/irresponsible, moral/
immoral, etc. (Adam, 2005; Davis & Flowers, 2011;
Doyal, 2013; Flowers, 2010; Flowers, Duncan, &
Frankis, 2000; Keogh, 2008a, 2008b; Kinsman, 1996). We
can also identify relevant events or narratives in people’s
biographical construction, for example, testing for HIV,
HIV diagnosis, illnesses, changes in clinical markers
(viral load or CD4 count) and starting treatments which
each hold considerable significance for that individual.
PPTs have the potential to disrupt such identities and
narratives. For example, by requiring those with a
negative diagnosis to take treatments, PrEP has the
potential to disrupt established distinctions between
sick and healthy or HIV-positive and HIV-negative.
Moreover, the status of key events in personal narratives
(such as an HIV test or commencing treatment) changes
as individuals test for different reasons and take various
actions depending on the result. Finally, the question of
locating the moral or responsible self becomes more
complex as PrEP and TasP are targeted to those at
greater risk through their sexual behaviours (Centers for
Disease Control and Prevention, 2013). For example,
delaying treatment initiation or sub-optimal adherence
may take on a moral dimension as viral suppression is
linked with potential for HIV transmission. Will those
not adhering be judged differently if they are seen to
increase the risk of infection to sexual partners?
To make better sense of people’s changing sense of
self, symposium participants proposed the deployment of
concepts such as therapeutic citizenship (Nguyen, Yapo
Ako, & Niamba, 2007) as a means of describing how
PWHIV negotiate the conflicting moral economies of
PPT implementation. Likewise, it was suggested that the
concept of biomedicalisation (Clarke, Mamo, Fosket,
Fishman, & Shim, 2010; Williams, Gabe, & Davis,
2009) may support theorisation of how identities are
shaped through embracing or resisting clinical technolo-
gies. Moreover, it was stressed that we require continuity
with past research focusing on rights, responsibilities and
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morality as individuals engage with HIV technologies
(Green & Sobo, 2000; Lupton, Mccarthy, & Chapman,
1995a, 1995b).
Finally, participants discussed the potential for PPTs
to interact with the self as inscribed within overarching
social structures. HIV epidemiology is stratified by
gender, ethnicity, social class and sexual identity. This
is due in part to factors associated with the biology of
HIV transmission but is also reflective of social/power
inequities. PPTs offer the potential for individuals,
especially women, to take greater control of their own
transmission risk. Thus, we should explore how PPT
implementation might be mediated by structural differ-
ence and how PPTs might re-balance structural asym-
metries through shifting the control of sexual risk.
Domain 2: intimacy, risk and sex
The imperative to engage with sexual HIV risk defines
the parameters of intimate relationships and constrains
sexual and reproductive decision-making for PWHIV
(Anderson & Weatherburn, 2004; Bourne, Dodds,
Keogh, Weatherburn, & Hammond, 2009; Bourne,
Dodds, Weatherburn, & Keogh, 2011; Bourne, Hickson,
Keogh, Reid, & Weatherburn, 2012; Davis et al., 2002;
Green & Sobo, 2000; Keogh, Weatherburn, & Stephens,
1999; Klitzman & Bayer, 2003; Marks & Crepaz, 2001;
Persson, 2008; Van de Ven, Kippax, Knox, Prestage, &
Crawford, 1999). Landscapes of risk may be redrawn by
PPTs with individuals having additional factors to weigh
up in calibrating their sexual risk practices. Moreover,
potential for new relationships may develop. For
example, sero-different relationships may be more feas-
ible if responsibility for avoiding infection is increas-
ingly shared (that is, where both partners are taking
ARVs and engaging with the clinic together, and using
clinical markers to negotiate risk).
Conceptualisations of individual risk propensities
have shifted towards a conception that sexual HIV risk
involves individuals negotiating protean “landscapes of
risk” (Green & Sobo, 2000; Lupton, 1999). Thus
reductive or deficit models of risk have been supplanted
by an approach that characterises risk as productive in
terms of the self and the possibilities afforded by
intimate relationships. Technologies that increase com-
plexity around risk, and promote the agency of those
living with that risk, have the potential to shift us further
from past deficit models. Conversely, however, as they
also herald greater involvement of the clinical sciences in
measuring the impact of PPTs on risk behaviour, we may
also see a resurgence of research utilising positivist
models of risk.
Domain 3: communities, resistance and activism
PPTs imply that people’s experience of and relationship
with the virus and the clinic will change. Many people
who have received a negative HIV diagnosis will be the
subjects of medical interventions akin to those who have
been diagnosed positive. As the identities/self-concept of
“HIV-positive” and “HIV-negative” lose definitional
power so too will they alter in terms of their collective,
political and cultural meanings. Such meanings have
been instrumental in defining interest groups united by
common experiences (for example, PWHIV, gay men/
MSM and African communities) and determining how
groups have organised themselves to attain political ends
(Altman, 1994; Berridge, 1996; Epstein, 1998; Hey-
wood, 2009; James, 2011). Although community forma-
tions will retain social and political currency,
relationships within and between them are likely to
change as are the aims and methods of AIDS activism.
PPTs appear to be already having an impact on such
relationships with the interests of AIDS activists, treat-
ment advocates, communities, drugs companies, clinical
providers and governments increasingly difficult to
unpick. Moreover, enthusiasm for PPTs is unlikely to
be shared equally in all quarters. For example, human
rights concerns are emerging regarding compulsion to
comply with treatments (European AIDS Treatment
Group, 2014; GNP+, 2012; International AIDS Alliance,
2012). Reassurance is needed that clinical and treatment
decisions will be guided by clinical need rather than cost.
At the symposium, attention focused on the extent to
which social scientists should engage in activist and/or
communitarian agendas around PPTs. It was argued that
the limited notions of “patient and public involvement”
relied upon by UK research councils should be chal-
lenged by social researchers. Of considerable concern is
the way in which social research on PPTs is predomi-
nantly conceived within clinical research models which
tend to utilise positivist approaches. The social sciences
can offer more meaningful participatory research models
while being mindful of the ways in which knowledge
production can generate or consolidate power asymmet-
ries. Finally, social sciences emphasise exploratory and
speculative approaches alongside positivistic or experi-
mental approaches. Such approaches were seen as
essential to ensure that research in this area is produced
with, by and for PWHIV.
Domain 4: systems, structures and institutions
In the history of PPT development, key moments
function as drivers. The Swiss Statement (Vernazza,
2008), the publication of HTPN 052 data (Cohen,
Chen, McCauley, Gamble, & Bollinger, 2011), the iPrEx
study results (Grant et al., 2010), the licensing of
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Truvada as PrEP in the USA (US Food and Drug
Administration, 2012) and discussions of a “functional
cure” in 2013 (Persaud, 2013; Pollack & McNeil, 2013)
are all examples of key moments which make PPT
implementation appear increasingly inevitable. Less well
known are scientific results that fail to support this
momentum, where evidence of efficacy is equivocal, or
models of roll-out suggest a lack-lustre epidemiological
impact. Those working in science and technology studies
are best placed to examine the ways in which systems,
structures and institutions work to exploit or ignore such
findings.
Moreover, as new prevention options emerge, the
meanings and associations traditionally ascribed to HIV
may be further re-framed. There is a potential, for
instance, to reconsider the collective protections that
widespread treatment access can afford entire popula-
tions (not just those who are already infected). This
framing would contrast strongly with the individualised
and stigmatised perceptions of the pre-ARV epidemic.
The ways in which systems, institutions and structures
utilise such a re-framing will be a key area of study
(continuing work examining systemic responses in light
of the introduction of ARVs post-1996; Moatti, Marlink,
Luchini, & Kazatchkine, 2008; Nixon, Hanass-Hancock,
Whiteside, & Barnett, 2011; Piot & Coll Seck, 2001;
Yeatman & Dowsett, 2009). For example, arguments
about the public health benefits of TasP have convinced
the UK Government to remove charges for HIV treat-
ment for those without recourse to public funds (Depart-
ment of Health, 2012). Health policy analysts may seek
to examine the way in which public health arguments
shifted a policy that has proven immune to human rights
advocacy campaigns.
Institutions such as clinics and voluntary agencies are
already collaborating on the systemic delivery of PPTs.
However these same institutions – for cultural, discip-
linary, pragmatic, resourcing and territorial reasons – will
also conflict, obfuscate or delay the progress of the PPT
agenda. For example, evidence demonstrates resistance
or ambivalence towards early initiation of ARV treat-
ment among those who expected to prescribe it (Persson,
2013; Vernooji, 2013). Those studying health systems
delivery, organisational sociology and policy analysis
will find opportunities to explore the shifts, tensions and
breakthroughs that impact how PPTs are conceptualised,
managed and delivered at a systems level. With regard to
implementation analysis, work is needed to understand
the knowledge, attitude and skill capacities for those
providing interventions around PPT uptake. Further-
more, in high-income countries with concentrated epi-
demics, initial PPT policy and clinical guidance appears
to encourage targeting of patient groups most likely to
benefit and sustain adherence. Adequate understanding
of the dynamics of implementation of such guidance will
require, for example, analyses of consultant and patient
interactions that incorporate theoretical understandings
of power relations via social stratification and stigmatis-
ing processes.
Domain 5: economic considerations and analyses
In the UK (particularly England), severe public sector
funding cuts have accompanied an overhaul of England’s
National Health Service (NHS) which shifts responsib-
ility for the delivery and oversight of public health. The
infrastructure and pharmaceutical costs required to
implement PPT policies are pressing concerns for those
tasked with clinical delivery within this already highly
pressurised context. Moreover, there are resourcing
implications beyond the provision of the pharmaceuticals
themselves. For example, TasP implementation requires
frequent clinical contact and regular monitoring of
patients’ CD4 counts and viral loads. This is at odds
with arms-length models for clinical management of
stable patient being developed to ease the burden on
clinical resources (Adams, Ogden, Erlich, & Hay, 2013;
Asboe et al., 2012). Moreover, there are questions about
the abilities of the NHS to meet treatment budgets in the
longer term. For example, London health care commis-
sioners have already explored the feasibility of asking
patients to switch to a less expensive treatment regime
due to local fiscal pressures (National AIDS Trust,
2012). Finally, there are potential sectoral difficulties.
For example, it is difficult to know how the Commis-
sioning Board of the NHS in England (which commis-
sions HIV care and treatment) will respond to calls for
resourcing for preventive outcomes (which are now the
responsibility of local government and which they may
well consider beyond their remit). Feasibility studies of
required frequency of HIV clinic visits, transferring of
routine HIV care to primary care, and the potential for
self-administered CD4 and viral load tests will assist our
understanding of the economic implications of routinised
self-care on PPT implementation. Moreover, there are
ethical questions to be asked about the potential impacts
of treatment plans that lack financial sustainability.
PPT clinical guideline development will inevitably
necessitate the generation of cost effectiveness evidence
within the NHS context. It is prescient for social
scientists to start framing the types of questions that
such evaluations should seek to answer. An array of
services will compose PPT delivery including HIV
testing, diagnostics, clinical and community services.
Evaluations should consider the systemic costs and
benefits, rather than simply considering treatment costs
in isolation. Such economic evaluations are already
under way in low and medium resource settings (Peter
Vickerman and colleagues, personal communication,
June 10, 2013) and should also be put into effect in
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high-income countries with concentrated epidemics. In
addition, such evaluations will need to take into account
the various investments that are required at each stage
along the patient trajectory given the considerable
dropout rates that are known to occur at each stage
(increasingly referred to as the “Treatment Cascade”;
Gardner, McLees, Steiner, del Rio, & Burman, 2011).
Domain 6: evaluation and outcomes
Symposium participants stressed lack of consensus
regarding complex evaluation approaches as an inhibitor
to evaluation of behavioural HIV prevention pro-
grammes in the UK. For example, biomedical and social
science disciplines differ on outcome indicators, the
former favouring clinical or epidemiological markers
and the latter interim measures such as changes in
knowledge, attitudes and behaviour. Consensus about
appropriate indicators is essential, and promising
approaches that may help us achieve a better collective
understanding of PPTs efficacy, effectiveness, impact
and delivery were cited. At this stage in the potential
implementation of PPTs, the role of mathematical
modellers is likely to be important in policy development
and planning, given their capacity to test a range of
hypotheses and implementation variables. With improved
collaboration between social scientists, clinicians and
modellers, increasingly reliable variables can be selected
for use. The work of the HIV Modelling Consortium
considers the starting points for understanding and
interpreting the complex relationships between PPTs,
HIV prevention behavioural interventions and behavi-
oural change (The HIV Modelling Consortium Treat-
ment as Prevention Editorial Writing Group, 2012).
In the longer term, given the research funding
environment in the UK, the symposium also noted that
we are likely to be reliant upon naturalistic experimental
approaches when designing complex evaluations of
PPTs. It remains unclear how such approaches will be
balanced with the imperative to carry out experimental
implementation trials considering the ethical, resource
and methodological challenges they entail.
Finally, as alluded to in prior sections, a policy
analysis approach that incorporates the methods used by
those in science and technology studies and the soci-
ology of knowledge will also be essential to understand
how and why particular research findings are widely
known and counted as “evidence” of effectiveness, while
others are not.
Discussion: overarching consensus points
The wide-ranging discussion prompted through this
consultative process indicates substantial interest in
PPTs from social scientists in the UK and a desire for a
robust social scientific response to the challenges and
opportunities presented. The complexity of these chal-
lenges was recognised in the main symposium consensus
point: that social scientific research in this area should be
interdisciplinary, should employ a range of methodolo-
gical and theoretical approaches and should be inclusive
and multi-perspectival. These principles were seen as
having the greatest capacity to generate useful, strategic
and ethically robust research.
Participants distinguished between research that
facilitates and evaluates PPT implementation and
research that problematises this implementation. The
former will need to engage meaningfully with clinical
and implementation studies whilst the latter should
critique knowledge production around PPTs and the
way that they are being codified in clinical and public
health discourses. Though these approaches should not
be seen as oppositional or antagonistic, the relationship
between them will always be troubled. Implementation
and evaluative work should incorporate and respond to
its own critiques and engage with research that theorises
or problematises PPTs.
As PPTs touch on intimate, social and structural
contexts, symposium participants called for inclusive
research collaborations. Implementation and evaluation
research necessitates joint-working between clinicians and
social scientists from diverse backgrounds including
epidemiologists, demographers, modellers, statisticians,
economists, health service researchers, medical and cul-
tural sociologists and community-based researchers.
Moreover, research should be methodologically diverse,
including experimental designs, natural experiments, sur-
veys, qualitative and participatory/community approaches.
The skills of modellers in the design of evaluations will be
essential. Limited resources will necessitate creative
evaluative methodologies, the coordination of contribu-
tions from a range of backgrounds and the employment of
strategic planning devices such as gap analyses and logic
models.
Given that PPTs are an evolution rather than a
revolution, continuity with past HIV research is essential.
Participants stressed the need to revisit sociological
concepts such as stigma and sick role in the light of
PPTs and to consider similar innovations (such as the
oral contraceptive pill) and other disease areas (such as
breast and lung cancer and epilepsy) that have been the
subject of sociological scrutiny.
Participants agreed that research funders should seek
to procure research that meaningfully includes PWHIV
as co-creators of knowledge. Such involvement implies
that future research should also seek to investigate
strengths as well as deficits in PPT implementation,
especially with regard to investigating the impact of
PPTs on sexual and emotional intimacy or pleasure.
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Finally, research commissioning needs to coordinate
the disparate activities that contribute to the evaluation
and the critique of PPT implementation. Such
coordination should recognise that research is often
conducted within a power-imbued system of funding
that exacerbates disparities between those with and
without funding to undertake specified research. Planning
needs to account for and overcome these differences.
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